These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 10953541)

  • 1. Selective COX-2 inhibitors and gastrointestinal mucosal injury: pharmacological and therapeutic considerations.
    Dajani EZ; Agrawal NM
    J Assoc Acad Minor Phys; 2000; 11(2-3):28-31. PubMed ID: 10953541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacology of selective COX-2 inhibitors.
    Capone ML; Tacconelli S; Sciulli MG; Patrignani P
    Int J Immunopathol Pharmacol; 2003; 16(2 Suppl):49-58. PubMed ID: 14552704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular and gastrointestinal toxicity of selective cyclo-oxygenase-2 inhibitors in man.
    Dajani EZ; Islam K
    J Physiol Pharmacol; 2008 Aug; 59 Suppl 2():117-33. PubMed ID: 18812633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy.
    Wolfe F; Anderson J; Burke TA; Arguelles LM; Pettitt D
    J Rheumatol; 2002 Mar; 29(3):467-73. PubMed ID: 11908558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonsteroidal anti-inflammatory drugs and lower gastrointestinal complications.
    Lanas A; Sopeña F
    Gastroenterol Clin North Am; 2009 Jun; 38(2):333-52. PubMed ID: 19446262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of selective cyclooxygenase-2 inhibitors on anti-ulcer medication and non-steroidal anti-inflammatory drug use in patients with rheumatic disease.
    Joshua FF; Oakley SP; Major GA
    Intern Med J; 2004 Apr; 34(4):153-61. PubMed ID: 15086694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The gastrointestinal effects of nonselective NSAIDs and COX-2-selective inhibitors.
    Laine L
    Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):25-32. PubMed ID: 12528071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Secondary and primary prophylaxis of gastropathy associated with nonsteroidal antiinflammatory drugs or low-dose-aspirin: a review based on four clinical scenarios].
    Limmer S; Ittel TH; Wietholtz H
    Z Gastroenterol; 2003 Aug; 41(8):719-28. PubMed ID: 12910426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gastrointestinal safety of novel nonsteroidal antiinflammatory drugs: selective COX-2 inhibitors and beyond.
    Coruzzi G; Venturi N; Spaggiari S
    Acta Biomed; 2007 Aug; 78(2):96-110. PubMed ID: 17933277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prevention and treatment of non-steroidal anti-inflammatory drug gastroenteropathy].
    Lanas A
    Rev Gastroenterol Mex; 2004; 69(4):251-60. PubMed ID: 15765979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Underutilization of preventive strategies in patients receiving NSAIDs.
    Sturkenboom MC; Burke TA; Dieleman JP; Tangelder MJ; Lee F; Goldstein JL
    Rheumatology (Oxford); 2003 Nov; 42 Suppl 3():iii23-31. PubMed ID: 14585915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors associated with the development of gastroduodenal ulcers due to the use of NSAIDs.
    Wolfe MM
    Int J Clin Pract Suppl; 2003 Apr; (135):32-7. PubMed ID: 12723745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on cyclooxygenase inhibitors: has a third COX isoform entered the fray?
    Hersh EV; Lally ET; Moore PA
    Curr Med Res Opin; 2005 Aug; 21(8):1217-26. PubMed ID: 16083531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical experience with cyclooxygenase-2 inhibitors.
    Lanas A
    Rheumatology (Oxford); 2002 Apr; 41 Supp 1():16-22; discussion 35-42. PubMed ID: 12173276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective agents on the small bowel: a cross-sectional capsule enteroscopy study.
    Maiden L; Thjodleifsson B; Seigal A; Bjarnason II; Scott D; Birgisson S; Bjarnason I
    Clin Gastroenterol Hepatol; 2007 Sep; 5(9):1040-5. PubMed ID: 17625980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ulcers, Helicobacter pylori infection, platelets and gastrointestinal complications of non-steroidal anti-inflammatory drugs: what are the connections?
    McCarthy DM
    Eur J Surg Suppl; 2002; (587):89-99. PubMed ID: 16144207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osteoarthritis therapy--are there still unmet needs?
    Laufer S
    Rheumatology (Oxford); 2004 Feb; 43 Suppl 1():i9-15. PubMed ID: 14752170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic.
    Warner TD; Mitchell JA
    FASEB J; 2004 May; 18(7):790-804. PubMed ID: 15117884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Coxibs: cyclooxygenase-2 inhibitors].
    Turnheim K
    Wien Klin Wochenschr; 2001 Aug; 113(15-16):558-65. PubMed ID: 11571832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications.
    Lai KC; Chu KM; Hui WM; Wong BC; Hu WH; Wong WM; Chan AO; Wong J; Lam SK
    Am J Med; 2005 Nov; 118(11):1271-8. PubMed ID: 16271912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.